CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 34 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-28 | Hadas Nicole R. SVP, General Counsel, Sec. | Grant or award | +17,500 | 120,078 | ||
| 2018-02-28 | Hadas Nicole R. SVP, General Counsel, Sec. | Grant or award · Employee Stock Option (Right to buy) | +25,000 | 25,000 | ||
| 2018-02-28 | Butler John P. CEO and President | Grant or award | +88,900 | 408,814 | ||
| 2018-02-28 | Butler John P. CEO and President | Grant or award · Employee Stock Option (Right to buy) | +126,300 | 126,300 | ||
| 2018-02-28 | Amello Jason SVP, CFO & Treasurer | Grant or award | +19,500 | 87,236 | ||
| 2018-02-28 | Amello Jason SVP, CFO & Treasurer | Grant or award · Employee Stock Option (Right to buy) | +27,700 | 27,700 | ||
| 2018-02-28 | Tubridy Karen L SVP, Chief Development Officer | Grant or award | +17,500 | 41,518 | ||
| 2018-02-28 | Tubridy Karen L SVP, Chief Development Officer | Grant or award · Employee Stock Option (Right to buy) | +25,000 | 25,000 | ||
| 2018-02-15 | Nash Duane Director | Sale | −1,000 | $14.62 | $15K | 21,499 |
| 2017-10-02 | Nash Duane Director | Sale | −1,188 | $19.64 | $23K | 22,499 |
| 2017-10-02 | Hadas Nicole R. SVP, General Counsel, Sec. | Sale | −1,553 | $19.64 | $31K | 108,054 |
| 2017-10-02 | Hadas Nicole R. SVP, General Counsel, Sec. | Sale | −6,250 | $19.95 | $125K | 101,804 |
| 2017-10-02 | Dahan Michel SVP, Chief Business Officer | Sale | −1,398 | $19.64 | $27K | 95,826 |
| 2017-09-28 | Dahan Michel SVP, Chief Business Officer | Sale | −5,000 | $19.30 | $97K | 97,224 |
| 2017-08-15 | Dahan Michel SVP, Chief Business Officer | Sale | −5,000 | $15.00 | $75K | 102,224 |
| 2017-07-05 | Satter Muneer A Director | Purchase | +1,034,482 | $14.50 | $15.0M | 3,037,042 |
| 2017-07-03 | Dahan Michel SVP, Chief Business Officer | Sale | −1,399 | $14.26 | $20K | 107,224 |
| 2017-07-03 | Hadas Nicole R. SVP, General Counsel, Sec. | Sale | −1,554 | $14.26 | $22K | 109,607 |
| 2017-07-03 | Nash Duane Director | Sale | −990 | $14.27 | $14K | 23,687 |
| 2017-06-15 | Renaud Ronald C JR Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 |
Page 22 of 27 · 537 trades